Review



clinical qsp model clinical abm software matlab  (MathWorks Inc)


Bioz Verified Symbol MathWorks Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    MathWorks Inc clinical qsp model clinical abm software matlab
    FIGURE 2 | Schematic diagram of human <t>QSP</t> model. Human QSP model was built by combining the reported model of Wang et al. [33] and a por- tion of oncolytic virus mechanism of action in the preclinical QSP model shown in Figure 1. APC, antigen-presenting cell; Arg-1, arginase 1; aTCD8, activated CD8-positive T cells; CCL-2, chemokine (C-C motif) ligand 2; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; e, rate of tumor-cell kill by differentiated effector T cells; IL-2, interleukin 2; IL-7, interleukin 7; IL-12, interleukin 12; mAPC, MHC-presenting APC; MDSC, myeloid- derived suppressor cells; MHC, major histocompatibility complex; nTCD4, naïve CD4-positive T cells; nTCD8, naïve CD8-positive T cells; NO, nitric oxide; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; QSP, quantitative systems pharmacology; TCR, T-cell receptor; Teff, effector T cells; Treg, regulatory T cells; Tumi, infected tumor cells; Tumni, noninfected tumor cells; Valpha, viral production size.
    Clinical Qsp Model Clinical Abm Software Matlab, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 97/100, based on 598 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/clinical+qsp+model+clinical+abm+software+matlab/SimBiology/pm39776360-198-0-6
    Average 97 stars, based on 598 article reviews
    clinical qsp model clinical abm software matlab - by Bioz Stars, 2026-09
    97/100 stars

    Images

    1) Product Images from "A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab."

    Article Title: A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab.

    Journal: CPT: pharmacometrics & systems pharmacology

    doi: 10.1002/psp4.13297

    FIGURE 2 | Schematic diagram of human QSP model. Human QSP model was built by combining the reported model of Wang et al. [33] and a por- tion of oncolytic virus mechanism of action in the preclinical QSP model shown in Figure 1. APC, antigen-presenting cell; Arg-1, arginase 1; aTCD8, activated CD8-positive T cells; CCL-2, chemokine (C-C motif) ligand 2; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; e, rate of tumor-cell kill by differentiated effector T cells; IL-2, interleukin 2; IL-7, interleukin 7; IL-12, interleukin 12; mAPC, MHC-presenting APC; MDSC, myeloid- derived suppressor cells; MHC, major histocompatibility complex; nTCD4, naïve CD4-positive T cells; nTCD8, naïve CD8-positive T cells; NO, nitric oxide; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; QSP, quantitative systems pharmacology; TCR, T-cell receptor; Teff, effector T cells; Treg, regulatory T cells; Tumi, infected tumor cells; Tumni, noninfected tumor cells; Valpha, viral production size.
    Figure Legend Snippet: FIGURE 2 | Schematic diagram of human QSP model. Human QSP model was built by combining the reported model of Wang et al. [33] and a por- tion of oncolytic virus mechanism of action in the preclinical QSP model shown in Figure 1. APC, antigen-presenting cell; Arg-1, arginase 1; aTCD8, activated CD8-positive T cells; CCL-2, chemokine (C-C motif) ligand 2; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; e, rate of tumor-cell kill by differentiated effector T cells; IL-2, interleukin 2; IL-7, interleukin 7; IL-12, interleukin 12; mAPC, MHC-presenting APC; MDSC, myeloid- derived suppressor cells; MHC, major histocompatibility complex; nTCD4, naïve CD4-positive T cells; nTCD8, naïve CD8-positive T cells; NO, nitric oxide; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; QSP, quantitative systems pharmacology; TCR, T-cell receptor; Teff, effector T cells; Treg, regulatory T cells; Tumi, infected tumor cells; Tumni, noninfected tumor cells; Valpha, viral production size.

    Techniques Used: Virus, Derivative Assay, Immunopeptidomics, Infection

    Related Articles

    Software:

    Article Title: A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab.
    Article Snippet: Conflicts of Interest A.Y., S.T., S.N., N.A., T.N., M.T., and K.K. are employees of Astellas Pharma Inc., Tokyo, Japan, and may own stock or stock options in the TABLE 1 | A summary comparing clinical QSP model and clinical ABM. .. Clinical QSP model Clinical ABM Software MATLAB, SimBiology Virtual Tumour (coded in MATLAB) Number of equations 160 67 Number of species 124 34 Number of parameters 185 47 Time to run Approximately 2 h Around 90 s per individual simulation (overall run time depends on the number of individual simulations required) Output No clear difference was observed. ..



    Similar Products

    clinical qsp model clinical abm software matlab  (MathWorks Inc)
    97
    MathWorks Inc clinical qsp model clinical abm software matlab
    FIGURE 2 | Schematic diagram of human <t>QSP</t> model. Human QSP model was built by combining the reported model of Wang et al. [33] and a por- tion of oncolytic virus mechanism of action in the preclinical QSP model shown in Figure 1. APC, antigen-presenting cell; Arg-1, arginase 1; aTCD8, activated CD8-positive T cells; CCL-2, chemokine (C-C motif) ligand 2; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; e, rate of tumor-cell kill by differentiated effector T cells; IL-2, interleukin 2; IL-7, interleukin 7; IL-12, interleukin 12; mAPC, MHC-presenting APC; MDSC, myeloid- derived suppressor cells; MHC, major histocompatibility complex; nTCD4, naïve CD4-positive T cells; nTCD8, naïve CD8-positive T cells; NO, nitric oxide; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; QSP, quantitative systems pharmacology; TCR, T-cell receptor; Teff, effector T cells; Treg, regulatory T cells; Tumi, infected tumor cells; Tumni, noninfected tumor cells; Valpha, viral production size.
    Clinical Qsp Model Clinical Abm Software Matlab, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/clinical+qsp+model+clinical+abm+software+matlab/SimBiology/pm39776360-198-0-6
    Average 97 stars, based on 1 article reviews
    clinical qsp model clinical abm software matlab - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 2 | Schematic diagram of human QSP model. Human QSP model was built by combining the reported model of Wang et al. [33] and a por- tion of oncolytic virus mechanism of action in the preclinical QSP model shown in Figure 1. APC, antigen-presenting cell; Arg-1, arginase 1; aTCD8, activated CD8-positive T cells; CCL-2, chemokine (C-C motif) ligand 2; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; e, rate of tumor-cell kill by differentiated effector T cells; IL-2, interleukin 2; IL-7, interleukin 7; IL-12, interleukin 12; mAPC, MHC-presenting APC; MDSC, myeloid- derived suppressor cells; MHC, major histocompatibility complex; nTCD4, naïve CD4-positive T cells; nTCD8, naïve CD8-positive T cells; NO, nitric oxide; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; QSP, quantitative systems pharmacology; TCR, T-cell receptor; Teff, effector T cells; Treg, regulatory T cells; Tumi, infected tumor cells; Tumni, noninfected tumor cells; Valpha, viral production size.

    Journal: CPT: pharmacometrics & systems pharmacology

    Article Title: A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab.

    doi: 10.1002/psp4.13297

    Figure Lengend Snippet: FIGURE 2 | Schematic diagram of human QSP model. Human QSP model was built by combining the reported model of Wang et al. [33] and a por- tion of oncolytic virus mechanism of action in the preclinical QSP model shown in Figure 1. APC, antigen-presenting cell; Arg-1, arginase 1; aTCD8, activated CD8-positive T cells; CCL-2, chemokine (C-C motif) ligand 2; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; e, rate of tumor-cell kill by differentiated effector T cells; IL-2, interleukin 2; IL-7, interleukin 7; IL-12, interleukin 12; mAPC, MHC-presenting APC; MDSC, myeloid- derived suppressor cells; MHC, major histocompatibility complex; nTCD4, naïve CD4-positive T cells; nTCD8, naïve CD8-positive T cells; NO, nitric oxide; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; QSP, quantitative systems pharmacology; TCR, T-cell receptor; Teff, effector T cells; Treg, regulatory T cells; Tumi, infected tumor cells; Tumni, noninfected tumor cells; Valpha, viral production size.

    Article Snippet: Clinical QSP model Clinical ABM Software MATLAB, SimBiology Virtual Tumour (coded in MATLAB) Number of equations 160 67 Number of species 124 34 Number of parameters 185 47 Time to run Approximately 2 h Around 90 s per individual simulation (overall run time depends on the number of individual simulations required) Output No clear difference was observed.

    Techniques: Virus, Derivative Assay, Immunopeptidomics, Infection